FDA records identify Shoulder Innovations, Inc. at 1535 Steele Ave. SW, Suite B, Grand Rapids, Michigan, as the applicant for premarket notifications covering shoulder joint prostheses. The most recent record in this collection is K262173 for the N22 Offset Humeral Head, a Traditional 510(k) received June 26, 2026 and decided September 8, 2026 as Substantially Equivalent under 21 CFR 888.3650, product code KWT, with Mark Hanes listed as contact. The company’s own announcement, published September 10, 2026, describes the N-22 Humeral Head as a titanium implant option for patients with metal hypersensitivity and states that a full commercial launch began. [1][2][4][5]

The N22 Offset Humeral Head clearance

K262173 covers the N22 Offset Humeral Head under regulation 21 CFR 888.3650, classification name Prosthesis, Shoulder, Non-Constrained, Metal/Polymer Cemented, device class 2, review panel Orthopedic. The FDA record lists product codes KWT, KWS and HSD, a Traditional clearance type, no third-party review, and a Summary rather than a full statement. The decision letter dated September 8, 2026 states that differences from the predicate do not raise different questions of safety and effectiveness and that the proposed device is as safe and effective as the legally marketed predicate. [1][2][3]

Independent indexes of the same filing repeat the applicant, product code, regulation and decision date, which makes the identity of the applicant and the scope of the clearance consistent across public records. Those indexes describe the device only at the level of name, classification and decision; they do not add clinical data or marketing claims. [8][9]

Earlier shoulder system filings

K241817 covers the InSet Total Shoulder System, filed by Shoulder Innovations, Inc. from the same Grand Rapids address, received June 24, 2024 and decided February 11, 2025 as Substantially Equivalent. It sits under 21 CFR 888.3650 with primary product code KWT and subsequent codes HSD and KWS, Traditional review, no third-party review and no combination product status. [7]

A separate determination for the N22 EZ Glenosphere, K252516, was dated January 15, 2026 and lists Mark D. Hanes, Ph.D., Senior Technical Director, as the submitter contact. That device is classified as a Shoulder Joint Metal/Polymer Semi-Constrained Cemented Prosthesis under 21 CFR 888.3660 and 888.3670, codes PHX and MBF, with the Inset Reverse Total Shoulder System (K210533) as primary predicate and the Identity Shoulder System (K213856) as reference device. [6]

How the company describes the N-22 line

The manufacturer’s release, issued from Grand Rapids on September 10, 2026, states that the N-22 Humeral Head is a titanium implant option for patients with metal hypersensitivity and calls it the second product introduction on a new line of technologies for metal-sensitive patients. The release identifies the company as commercial-stage and focused on the shoulder surgical care market, and lists NYSE: SI as its ticker. Those characterizations come from the publisher, not from FDA records. [4][5]

The release does not document the composition of every product on that line, and the FDA records in this collection describe the N22 Offset Humeral Head by classification and predicate comparison rather than by materials. Claims about the broader line therefore remain limited to what the manufacturer states about the N-22 Humeral Head itself. [2][4]

What the filing record does and does not show

The linked collection for this company contains one 510(k) record, K262173, decided SESE; the smaller record sample used for filing examples contains that same single entry. These counts describe the filings assembled here as of November 20, 2026 and are not measures of total company sales, total portfolio or safety performance. The additional filings discussed above appear in the numbered sources but not in that linked collection. [1][6][7]

No recall records are associated with this company in the collection, and the sources do not establish ownership structure, headquarters separate from the filing address, customers, certifications or independent test results. The filing address is an FDA correspondence address and should not be read as a corporate headquarters designation. [1][2][7]